LC
ZYNE

Lindbrook Capital’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Lindbrook Capital’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$1 – 2866
2023
Q3 		$1 Hold
1
– – ﹤0.01% 2684
2023
Q2 		$0 Hold
1
– – ﹤0.01% 2892
2023
Q1 		$0 Hold
1
– – ﹤0.01% 2949
2022
Q4 		$1 Hold
1
– – ﹤0.01% 2820
2022
Q3 		$0 Hold
1
– – ﹤0.01% 2992
2022
Q2 		$0 Hold
1
– – ﹤0.01% 2853
2022
Q1 		$0 Buy
+1
New +$2 ﹤0.01% 2655

Lindbrook Capital's ZYNE Position: Q4 2023 in Review

Lindbrook Capital sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 1 share — an estimated $1 sold.

Lindbrook Capital first reported a position in ZYNE in Q1 2022 and held it in 7 quarters. The position peaked at $1 in Q3 2023. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.

  • Lindbrook Capital reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
  • Lindbrook Capital sold 1 Zynerba Pharmaceuticals, Inc share in Q4 2023, an estimated $1.
  • Lindbrook Capital first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2022 and held it in 7 quarters.
  • Lindbrook Capital's Zynerba Pharmaceuticals, Inc position peaked at $1 in Q3 2023.
  • 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.

Based on Lindbrook Capital's 13F filing for Q4 2023, filed 1 Feb 2024.